Literature DB >> 19194304

Patient reported symptoms during an ulcerative colitis flare: a Qualitative Focus Group Study.

Akbar K Waljee1, Joel C Joyce, Patricia A Wren, Tahira M Khan, Peter D R Higgins.   

Abstract

BACKGROUND: It has been assumed that the symptoms measured in disease activity indices for ulcerative colitis reflect those symptoms that patients find useful in evaluating the severity of a disease flare.
OBJECTIVE: We aimed to identify which symptoms are important to patients and to compare these symptoms with a comprehensive list of commonly measured symptoms to evaluate whether the patient-reported important symptoms are represented in current disease activity indices for ulcerative colitis.
METHODS: Qualitative focus group study.
RESULTS: Patients in this sample confirmed 15 symptoms but not 11 other symptoms found in common ulcerative colitis activity indices. Patients identified an additional 14 symptoms not included in commonly used ulcerative colitis activity indices, which they believed to be important in evaluating the onset or severity of an ulcerative colitis flare.
CONCLUSION: Current indices capture only a portion of the clinical symptoms that are important to patients in an ulcerative colitis flare, and may neither accurately measure nor fully reflect patients' experience of ulcerative colitis. These findings present an opportunity to develop better patient-centered measures of ulcerative colitis.

Entities:  

Mesh:

Year:  2009        PMID: 19194304      PMCID: PMC3193174          DOI: 10.1097/MEG.0b013e328326cacb

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  23 in total

1.  Cortisone in ulcerative colitis; final report on a therapeutic trial.

Authors:  S C TRUELOVE; L J WITTS
Journal:  Br Med J       Date:  1955-10-29

2.  An index of disease activity in patients with ulcerative colitis.

Authors:  M Seo; M Okada; T Yao; M Ueki; S Arima; M Okumura
Journal:  Am J Gastroenterol       Date:  1992-08       Impact factor: 10.864

3.  Evaluation of disease activity in patients with moderately active ulcerative colitis: comparisons between a new activity index and Truelove and Witts' classification.

Authors:  M Seo; M Okada; T Yao; N Okabe; K Maeda; K Oh
Journal:  Am J Gastroenterol       Date:  1995-10       Impact factor: 10.864

4.  Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.

Authors:  K W Schroeder; W J Tremaine; D M Ilstrup
Journal:  N Engl J Med       Date:  1987-12-24       Impact factor: 91.245

5.  Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study.

Authors:  W R Best; J M Becktel; J W Singleton; F Kern
Journal:  Gastroenterology       Date:  1976-03       Impact factor: 22.682

6.  Cyclosporine in severe ulcerative colitis refractory to steroid therapy.

Authors:  S Lichtiger; D H Present; A Kornbluth; I Gelernt; J Bauer; G Galler; F Michelassi; S Hanauer
Journal:  N Engl J Med       Date:  1994-06-30       Impact factor: 91.245

Review 7.  Review article: patients' fears and unmet needs in inflammatory bowel disease.

Authors:  E J Irvine
Journal:  Aliment Pharmacol Ther       Date:  2004-10       Impact factor: 8.171

8.  A simple clinical colitis activity index.

Authors:  R S Walmsley; R C Ayres; R E Pounder; R N Allan
Journal:  Gut       Date:  1998-07       Impact factor: 23.059

9.  5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis.

Authors:  L R Sutherland; F Martin; S Greer; M Robinson; N Greenberger; F Saibil; T Martin; J Sparr; E Prokipchuk; L Borgen
Journal:  Gastroenterology       Date:  1987-06       Impact factor: 22.682

10.  Factors affecting colectomy rate in ulcerative colitis: an epidemiologic study.

Authors:  C E Leijonmarck; P G Persson; G Hellers
Journal:  Gut       Date:  1990-03       Impact factor: 23.059

View more
  17 in total

1.  Gut-directed hypnotherapy significantly augments clinical remission in quiescent ulcerative colitis.

Authors:  L Keefer; T H Taft; J L Kiebles; Z Martinovich; T A Barrett; O S Palsson
Journal:  Aliment Pharmacol Ther       Date:  2013-08-19       Impact factor: 8.171

2.  The burden of inflammatory bowel disease: a patient-reported qualitative analysis and development of a conceptual model.

Authors:  Jennifer Devlen; Kathleen Beusterien; Linnette Yen; Awais Ahmed; Adam S Cheifetz; Alan C Moss
Journal:  Inflamm Bowel Dis       Date:  2014-03       Impact factor: 5.325

3.  Increased DMT1 and FPN1 expression with enhanced iron absorption in ulcerative colitis human colon.

Authors:  Emily A Minor; Justin T Kupec; Andrew J Nickerson; Karthikeyan Narayanan; Vazhaikkurichi M Rajendran
Journal:  Am J Physiol Cell Physiol       Date:  2019-11-13       Impact factor: 4.249

4.  Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes.

Authors:  Julián Panés; Chinyu Su; Andrew G Bushmakin; Joseph C Cappelleri; Carla Mamolo; Paul Healey
Journal:  BMC Gastroenterol       Date:  2015-02-05       Impact factor: 3.067

5.  Healthcare professionals' views of the use and administration of two salvage therapy drugs for acute ulcerative colitis: a nested qualitative study within the CONSTRUCT trial.

Authors:  Clare Clement; Frances Rapport; Anne Seagrove; Laith Alrubaiy; John Williams
Journal:  BMJ Open       Date:  2017-02-22       Impact factor: 2.692

Review 6.  Understanding the health and social care needs of people living with IBD: a meta-synthesis of the evidence.

Authors:  Karen Kemp; Jane Griffiths; Karina Lovell
Journal:  World J Gastroenterol       Date:  2012-11-21       Impact factor: 5.742

Review 7.  The Inflammatory Bowel Disease Questionnaire in Randomized Controlled Trials of Treatment for Ulcerative Colitis: Systematic Review and Meta-Analysis.

Authors:  Aaron Yarlas; Stephen Maher; Martha Bayliss; Andrew Lovley; Joseph C Cappelleri; Andrew G Bushmakin; Marco D DiBonaventura
Journal:  J Patient Cent Res Rev       Date:  2020-04-27

8.  What Is a Flare? The Manitoba Living With IBD Study.

Authors:  Kelcie Witges; Kathryn Sexton; Lesley A Graff; Laura E Targownik; Lisa M Lix; Clove Haviva; James Stone; Leigh Anne Shafer; Kathy Vagianos; Charles N Bernstein
Journal:  Inflamm Bowel Dis       Date:  2022-06-03       Impact factor: 7.290

9.  Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies.

Authors:  Julian Panés; Séverine Vermeire; James O Lindsay; Bruce E Sands; Chinyu Su; Gary Friedman; Haiying Zhang; Aaron Yarlas; Martha Bayliss; Stephen Maher; Joseph C Cappelleri; Andrew G Bushmakin; David T Rubin
Journal:  J Crohns Colitis       Date:  2018-01-24       Impact factor: 9.071

10.  Tofacitinib in Patients with Ulcerative Colitis: Inflammatory Bowel Disease Questionnaire Items in Phase 3 Randomized Controlled Induction Studies.

Authors:  Marla C Dubinsky; Marco DiBonaventura; Haiyun Fan; Andrew G Bushmakin; Joseph C Cappelleri; Eric Maller; Andrew J Thorpe; Leonardo Salese; Julian Panés
Journal:  Inflamm Bowel Dis       Date:  2021-06-15       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.